Mirova US LLC Decreases Position in Thermo Fisher Scientific Inc. $TMO

Mirova US LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 660,789 shares of the medical research company’s stock after selling 26,277 shares during the quarter. Thermo Fisher Scientific makes up approximately 3.2% of Mirova US LLC’s portfolio, making the stock its 12th largest holding. Mirova US LLC’s holdings in Thermo Fisher Scientific were worth $320,496,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. Norges Bank bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at about $2,264,615,000. Soundwatch Capital LLC bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $807,713,000. Flossbach Von Storch SE lifted its stake in Thermo Fisher Scientific by 93.0% in the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock worth $1,105,698,000 after purchasing an additional 1,314,182 shares in the last quarter. EdgePoint Investment Group Inc. boosted its holdings in Thermo Fisher Scientific by 282.5% in the 2nd quarter. EdgePoint Investment Group Inc. now owns 1,323,065 shares of the medical research company’s stock valued at $536,450,000 after purchasing an additional 977,127 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Thermo Fisher Scientific by 58.2% in the second quarter. The Manufacturers Life Insurance Company now owns 2,293,264 shares of the medical research company’s stock worth $929,828,000 after purchasing an additional 843,267 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Frederick M. Lowery sold 6,912 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $581.94, for a total value of $4,022,369.28. Following the transaction, the executive vice president owned 14,367 shares of the company’s stock, valued at $8,360,731.98. This trade represents a 32.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Michel Lagarde sold 22,046 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the completion of the transaction, the chief operating officer owned 84,117 shares of the company’s stock, valued at approximately $47,404,976.52. The trade was a 20.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 149,271 shares of company stock worth $86,507,282 over the last three months. 0.33% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Leerink Partners boosted their target price on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Citigroup upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and lifted their price target for the company from $580.00 to $660.00 in a research report on Thursday, December 11th. Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. Argus boosted their price target on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $616.60.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $584.41 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The firm has a market cap of $219.57 billion, a P/E ratio of 33.76, a P/E/G ratio of 4.12 and a beta of 0.90. The business’s 50 day moving average price is $574.75 and its 200-day moving average price is $505.32. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company’s revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has initiated a stock repurchase plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.